A Phase 1b, Adaptive, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Design Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Selnoflast (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 19 Sep 2024 Status changed from recruiting to completed.
- 06 Aug 2024 Planned End Date changed from 30 Jan 2025 to 18 Jul 2025.
- 06 Aug 2024 Planned primary completion date changed from 30 Jan 2025 to 18 Jul 2025.